inclusion criteria: 1. provide written informed consent 2. male or female subjects age \> 18 years at the time of signing the informed consent form. 3. covid-19 positive according to diagnosis (evaluated by reverse transcription (rt)-polymerase chain reaction (pcr) test confirming infection with severe acute respiratory syndrome coronavirus and clinical management of covid-19 criteria (refer to appendix b) 4. individuals with moderate to severe covid-19 symptoms. * moderate: * patients with moderate disease are symptomatic (e.g. fever, cough, headache, myalgia, sore throat, nasal congestion, nausea, vomiting, diarrhea, fatigue, anosmia, or dysgeusia) and have abnormal chest imaging or some degree of hypoxia requiring supplemental oxygen but not intubation. * moderate-severe: * the moderately severe disease category includes patients who are symptomatic (as described above), have abnormal chest imaging, but also have worsening hypoxia compatible with mild acute respiratory distress syndrome (ards) (partial pressure of oxygen (pao2)/fraction of inspired oxygen (fio2) \</= 300 but \> 200) - berlin criteria; but do not yet require intubation . 5. adequate venous access 6. for female patients only, willingness to use fda-recommended birth control until 6 months post treatment. 7. must agree to comply with all study requirements and be willing to complete all study visits. 8. need in-patient admission

inclusion criteria: 1. provide written informed consent 2. male or female subjects age \> 18 years at the time of signing the informed consent form. 3. covid-19 positive according to diagnosis (evaluated by reverse transcription (rt)-polymerase chain reaction (pcr) test confirming infection with severe acute respiratory syndrome coronavirus and clinical management of covid-19 criteria (refer to appendix b) 4. individuals with moderate to severe covid-19 symptoms. * moderate: * patients with moderate disease are symptomatic (e.g. fever, cough, headache, myalgia, sore throat, nasal congestion, nausea, vomiting, diarrhea, fatigue, anosmia, or dysgeusia) and have abnormal chest imaging or some degree of hypoxia requiring supplemental oxygen but not intubation. * moderate-severe: * the moderately severe disease category includes patients who are symptomatic (as described above), have abnormal chest imaging, but also have worsening hypoxia compatible with mild acute respiratory distress syndrome (ards) (partial pressure of oxygen (pao2)/fraction of inspired oxygen (fio2) \</= 300 but \> 200) - berlin criteria; but do not yet require intubation . 5. adequate venous access 6. for female patients only, willingness to use fda-recommended birth control until 6 months post treatment. 7. must agree to comply with all study requirements and be willing to complete all study visits. 8. need in-patient admission

inclusion criteria: provide written informed consent male or female subjects age > 18 years at the time of signing the informed consent form. covid-19 positive according to diagnosis (evaluated by reverse transcription (rt)-polymerase chain reaction (pcr) test confirming infection with severe acute respiratory syndrome coronavirus and clinical management of covid-19 criteria (refer to appendix b) individuals with moderate to severe covid-19 symptoms. moderate: patients with moderate disease are symptomatic (e.g. fever, cough, headache, myalgia, sore throat, nasal congestion, nausea, vomiting, diarrhea, fatigue, anosmia, or dysgeusia) and have abnormal chest imaging or some degree of hypoxia requiring supplemental oxygen but not intubation. moderate-severe: the moderately severe disease category includes patients who are symptomatic (as described above), have abnormal chest imaging, but also have worsening hypoxia compatible with mild acute respiratory distress syndrome (ards) (partial pressure of oxygen (pao2)/fraction of inspired oxygen (fio2) </= 300 but > 200) - berlin criteria; but do not yet require intubation . adequate venous access for female patients only, willingness to use fda-recommended birth control until 6 months post treatment. must agree to comply with all study requirements and be willing to complete all study visits. need in-patient admission

inclusion criteria: provide written informed consent male or female subjects age > 18 years at the time of signing the informed consent form. covid-19 positive according to diagnosis (evaluated by reverse transcription (rt)-polymerase chain reaction (pcr) test confirming infection with severe acute respiratory syndrome coronavirus and clinical management of covid-19 criteria (refer to appendix b) individuals with moderate to severe covid-19 symptoms. moderate: patients with moderate disease are symptomatic (e.g. fever, cough, headache, myalgia, sore throat, nasal congestion, nausea, vomiting, diarrhea, fatigue, anosmia, or dysgeusia) and have abnormal chest imaging or some degree of hypoxia requiring supplemental oxygen but not intubation. moderate-severe: the moderately severe disease category includes patients who are symptomatic (as described above), have abnormal chest imaging, but also have worsening hypoxia compatible with mild acute respiratory distress syndrome (ards) (partial pressure of oxygen (pao2)/fraction of inspired oxygen (fio2) </= 300 but > 200) - berlin criteria; but do not yet require intubation . adequate venous access for female patients only, willingness to use fda-recommended birth control until 6 months post treatment. must agree to comply with all study requirements and be willing to complete all study visits. need in-patient admission

inclusion criteria: 1. provide written informed consent 2. male or female subjects age > 18 years at the time of signing the informed consent form. 3. covid-19 positive according to diagnosis (evaluated by reverse transcription (rt)-polymerase chain reaction (pcr) test confirming infection with severe acute respiratory syndrome coronavirus and clinical management of covid-19 criteria (refer to appendix b) 4. individuals with moderate to severe covid-19 symptoms. - moderate: - patients with moderate disease are symptomatic (e.g. fever, cough, headache, myalgia, sore throat, nasal congestion, nausea, vomiting, diarrhea, fatigue, anosmia, or dysgeusia) and have abnormal chest imaging or some degree of hypoxia requiring supplemental oxygen but not intubation. - moderate-severe: - the moderately severe disease category includes patients who are symptomatic (as described above), have abnormal chest imaging, but also have worsening hypoxia compatible with mild acute respiratory distress syndrome (ards) (partial pressure of oxygen (pao2)/fraction of inspired oxygen (fio2) </= 300 but > 200) - berlin criteria; but do not yet require intubation . 5. adequate venous access 6. for female patients only, willingness to use fda-recommended birth control until 6 months post treatment. 7. must agree to comply with all study requirements and be willing to complete all study visits. 8. need in-patient admission

inclusion criteria: 1. provide written informed consent 2. male or female subjects age > 18 years at the time of signing the informed consent form. 3. covid-19 positive according to diagnosis (evaluated by reverse transcription (rt)-polymerase chain reaction (pcr) test confirming infection with severe acute respiratory syndrome coronavirus and clinical management of covid-19 criteria (refer to appendix b) 4. individuals with moderate to severe covid-19 symptoms. - moderate: - patients with moderate disease are symptomatic (e.g. fever, cough, headache, myalgia, sore throat, nasal congestion, nausea, vomiting, diarrhea, fatigue, anosmia, or dysgeusia) and have abnormal chest imaging or some degree of hypoxia requiring supplemental oxygen but not intubation. - moderate-severe: - the moderately severe disease category includes patients who are symptomatic (as described above), have abnormal chest imaging, but also have worsening hypoxia compatible with mild acute respiratory distress syndrome (ards) (partial pressure of oxygen (pao2)/fraction of inspired oxygen (fio2) </= 300 but > 200) - berlin criteria; but do not yet require intubation . 5. adequate venous access 6. for female patients only, willingness to use fda-recommended birth control until 6 months post treatment. 7. must agree to comply with all study requirements and be willing to complete all study visits. 8. need in-patient admission